

Table 5.15
Cancer of the Cervix Uteri (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity and Years Since Diagnosis

| Years Since Diagnosis | 0 to 5 | > 5 to 10 | > 10 to 15 | > 15 to 20 | > 20 to 25 | <=25 ^b | > 25 ^d | Complete ^e |
|------------------------|--------|-----------|------------|------------|------------|-------------------|-------------------|-----------------------|
| <u>Race</u> | | | | | | | | |
| All Races | 43,448 | 37,001 | 35,416 | 37,194 | 34,102 | 187,161 | 104,544 | 291,704 |
| White | 34,188 | 30,114 | 29,094 | 30,785 | 28,686 | 152,866 | 90,098 | 242,964 |
| Black | 5,377 | 4,126 | 4,064 | 3,976 | 3,233 | 20,775 | 13,989 | 34,764 |
| Asian/Pacific Islander | 2,561 | 1,817 | 1,631 | 1,589 | 1,400 | 8,999 | + | + |
| Hispanic | 8,097 | 7,082 | 7,030 | 6,680 | 5,493 | 34,382 | + | + |

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence and Race/Ethnicity

| Age at Prevalence | Age Specific (Crude) | | | | | | | | | | Age-Adjusted ^c |
|------------------------|----------------------|-----|--------|--------|--------|--------|--------|--------|--------|--------|---------------------------|
| | All Ages | 0-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60-69 | 70-79 | 80+ | All Ages |
| <u>Race</u> | | | | | | | | | | | |
| All Races | 0.1138 | - | 0.0002 | 0.0078 | 0.0690 | 0.1947 | 0.2501 | 0.2282 | 0.1871 | 0.1341 | 0.1013 |
| White | 0.1198 | - | 0.0002 | 0.0082 | 0.0754 | 0.2109 | 0.2595 | 0.2262 | 0.1790 | 0.1222 | 0.1048 |
| Black | 0.0877 | - | 0.0003 | 0.0063 | 0.0492 | 0.1371 | 0.2069 | 0.2218 | 0.2120 | 0.1881 | 0.0875 |
| Asian/Pacific Islander | 0.0829 | - | - | 0.0042 | 0.0316 | 0.1053 | 0.1774 | 0.2269 | 0.2410 | 0.2093 | 0.0789 |
| Hispanic | 0.1195 | - | 0.0004 | 0.0075 | 0.0779 | 0.2125 | 0.3530 | 0.3956 | 0.3831 | 0.3049 | 0.1466 |

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.